- « Previous
- Clinical Pharmacology
- Next »
Lanoxin
CLINICAL PHARMACOLOGY
Lanoxin
Mechanism of Action: Digoxin inhibits sodium-potassium ATPase, an enzyme that regulates the quantity of sodium and potassium inside cells. Inhibition of the enzyme leads to an increase in the intracellular concentration of sodium and thus (by stimulation of sodium-calcium exchange) an increase in the intracellular concentration of calcium. The beneficial effects of digoxin result from direct actions on cardiac muscle, as well as indirect actions on the cardiovascular system mediated by effects on the autonomic nervous system. The autonomic effects include: (1) a vagomimetic action, which is responsible for the effects of digoxin on the sinoatrial and atrioventricular (AV) nodes; and (2) baroreceptor sensitization, which results in increased afferent inhibitory activity and reduced activity of the sympathetic nervous system and renin-angiotensin system for any given increment in mean arterial pressure. The pharmacologic consequences of these direct and indirect effects are: (1) an increase in the force and velocity of myocardial systolic contraction (positive inotropic action); (2) a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect); and (3) slowing of the heart rate and decreased conduction velocity through the AV node (vagomimetic effect). The effects of digoxin in heart failure are mediated by its positive inotropic and neurohormonal deactivating effects, whereas the effects of the drug in atrial arrhythmias are related to its vagomimetic actions. In high doses, digoxin increases sympathetic outflow from the central nervous system (CNS). This increase in sympathetic activity may be an important factor in digitalis toxicity.
Pharmacokinetics: Note: the following data are from studies performed in adults, unless otherwise stated.
Absorption: Comparisons of the systemic availability and equivalent doses for preparations of LANOXIN are shown in Table 1.
Table 1: Comparisons of the Systemic Availability and Equivalent Doses for Preparations of LANOXIN
| Product | Absolute Bioavailability | Equivalent Doses (mcg)* Among Dosage Forms | |||
| LANOXIN Tablets | 60 - 80% | 62.5 | 125 | 250 | 500 |
| LANOXIN Elixir Pediatric | 70 - 85% | 62.5 | 125 | 250 | 500 |
| LANOXICAPS® | 90 - 100% | 50 | 100 | 200 | 400 |
| LANOXIN Injection/IV | 100% | 50 | 100 | 200 | 400 |
| * For example, 125 mcg LANOXIN Tablets equivalent to 125 mcg LANOXIN Elixir Pediatric equivalent to 100 mcg LANOXICAPS equivalent to 100 mcg LANOXIN Injection/IV. | |||||
Generic Name: Digoxin
- « Previous
- Clinical Pharmacology
- Next »
Myoblasts for the Heart
Researchers are onto something that may allow the heart to repair itself, with the help of your own muscle cells.See more WebMD Videos »
WebMD Daily
Get breaking medical news.
